Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ProShares Ultra Nasdaq Biotechnology (BIB)

52.07
Delayed Data
As of Nov 20
 -0.94 / -1.77%
Today’s Change
38.82
Today|||52-Week Range
64.51
+30.47%
Year-to-Date

Investment Objective

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index-®. The fund invests in securities and derivatives that ProShare Advisors believes- in combination- should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

No recent news for ProShares Ultra Nasdaq Biotechnology.

Performance

1 month-13.87% 3 years-4.33%
3 months+1.98% 5 years+29.54%
1 year+12.64% Since inception+28.95%
Data through 11/21/2017

Quote Details

Previous close$53.01
Open day’s range51.91 – 53.31
Net asset value (NAV)52.03 (11/20/2017)
Daily volume201,590
Average volume (3 months)265,012
Data as of 4:00pm ET, 11/20/2017

Peer Comparisonvs. Trading--leveraged equity ETFs

 BIBCategory
Performance 5-yr return+29.54%+16.48%
Expense Gross exp ratio1.04%2.04%
Risk 5 year sharpe ratio0.85--
Net assets$438.6M$94.1M
Average market cap$16.7B--
Average P/E20.8--
Dividend / Share--0.31%

Competitors

SPLX UBS ETRACS Monthly Reset 2xLeveraged S&P...
SDYL UBS ETRACS Monthly Pay 2xLeveraged S&P D...
SFLA iPath® Long Extended S&P 500® TR Index...

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 36.52%
-- 23.63%
-- 21.76%
-- 15.33%
-- 8.67%
AMGN Amgen6.77%
BIIB Biogen6.77%
GILD Gilead Sciences6.16%
-- 5.33%
REGN Regeneron Pharmaceuticals5.08%